ImmuCell (NASDAQ:ICCC – Get Free Report) and Zynex (NASDAQ:ZYXI – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, valuation and risk.
Volatility and Risk
ImmuCell has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500. Comparatively, Zynex has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500.
Valuation & Earnings
This table compares ImmuCell and Zynex”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ImmuCell | $27.64 million | 2.78 | -$1.04 million | ($0.11) | -77.24 |
| Zynex | $108.20 million | 0.04 | $2.99 million | ($2.43) | -0.05 |
Zynex has higher revenue and earnings than ImmuCell. ImmuCell is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares ImmuCell and Zynex’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ImmuCell | -3.76% | -3.60% | -2.30% |
| Zynex | -68.35% | -804.30% | -36.67% |
Insider & Institutional Ownership
13.5% of ImmuCell shares are held by institutional investors. Comparatively, 29.7% of Zynex shares are held by institutional investors. 5.7% of ImmuCell shares are held by company insiders. Comparatively, 49.3% of Zynex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of recent recommendations for ImmuCell and Zynex, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ImmuCell | 1 | 0 | 0 | 0 | 1.00 |
| Zynex | 1 | 2 | 1 | 0 | 2.00 |
Zynex has a consensus price target of $4.90, suggesting a potential upside of 3,820.00%. Given Zynex’s stronger consensus rating and higher probable upside, analysts clearly believe Zynex is more favorable than ImmuCell.
Summary
Zynex beats ImmuCell on 9 of the 14 factors compared between the two stocks.
About ImmuCell
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
About Zynex
Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with MarketBeat.com's FREE daily email newsletter.
